Sakar Healthcare Ltd (IN:SAKAR)
:SAKAR
Want to see IN:SAKAR full AI Analyst Report?
SAKAR Stock Chart & Stats
₹406.55
-₹0.50(-0.17%)
At close: 4:00 PM EST
₹406.55
-₹0.50(-0.17%)
Day’s Range― - ―
52-Week Range₹306.00 - ₹829.60
Previous CloseN/A
Volume6.75K
Average Volume (3M)19.08K
Market Cap
₹17.76B
Enterprise Value₹17.82B
Total Cash (Recent Filing)₹2.16M
Total Debt (Recent Filing)₹718.62M
Price to Earnings (P/E)36.4
Beta0.44
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.87
Shares Outstanding21,949,910
10 Day Avg. Volume18,950
30 Day Avg. Volume19,083
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)3.42
Price to Sales (P/S)4.41
P/FCF Ratio100.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSakar has scaled revenue meaningfully, with FY2026 growth accelerating to 23.4%. Durable top-line expansion across domestic, export and contract manufacturing channels supports long-term market penetration, capacity utilization gains and the ability to invest in product development and distribution.
Leverage ReductionLeverage has declined materially to a conservative ~0.17, improving financial flexibility and lowering interest burden. This structural de-risking enhances capacity for capex, regulatory filings or selective M&A without stressing liquidity, and reduces bankruptcy and refinancing risk over the medium term.
Solid ProfitabilityProfitability on FY2026 shows durable operating strength: gross margin ~26.3% and net margin ~12.1%. These margin levels indicate the business earns healthy incremental returns on sales, supporting reinvestment and sustained operating cash generation if margins stabilize.
Bears Say
Weak Cash ConversionFCF improvement is encouraging, but free cash flow remains modest at ~28% of net income and operating cash flow relative to sales is still restrained. If cash conversion is not sustained, the company may need external funding for growth or face limits on dividends, buybacks or capex flexibility.
Margin VolatilityHistorical gross margins fell materially from the ~42%–46% range to ~26.3%, implying sensitivity to product mix, pricing or input-cost swings. Persistent margin volatility can erode earnings predictability and signals weaker pricing power or rising input pressures absent structural remediation.
Moderate ROEROE improvement to ~9.4% shows progress, but remains moderate for the sector. Structurally modest returns may reflect capital intensity, competitive pricing, or limited asset turnover, constraining long-term shareholder return potential and the company's capacity to attract incremental equity on favorable terms.
Sakar Healthcare Ltd News
SAKAR FAQ
What was Sakar Healthcare Ltd’s price range in the past 12 months?
Sakar Healthcare Ltd lowest stock price was ₹306.00 and its highest was ₹829.60 in the past 12 months.
What is Sakar Healthcare Ltd’s market cap?
Sakar Healthcare Ltd’s market cap is ₹17.76B.
When is Sakar Healthcare Ltd’s upcoming earnings report date?
Sakar Healthcare Ltd’s upcoming earnings report date is Aug 18, 2026 which is in 88 days.
How were Sakar Healthcare Ltd’s earnings last quarter?
Sakar Healthcare Ltd released its earnings results on May 12, 2026. The company reported ₹4.96 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.96.
Is Sakar Healthcare Ltd overvalued?
According to Wall Street analysts Sakar Healthcare Ltd’s price is currently Overvalued.
Does Sakar Healthcare Ltd pay dividends?
Sakar Healthcare Ltd does not currently pay dividends.
What is Sakar Healthcare Ltd’s EPS estimate?
Sakar Healthcare Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sakar Healthcare Ltd have?
Sakar Healthcare Ltd has 21,949,910 shares outstanding.
What happened to Sakar Healthcare Ltd’s price movement after its last earnings report?
Sakar Healthcare Ltd reported an EPS of ₹4.96 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 7.562%.
Which hedge fund is a major shareholder of Sakar Healthcare Ltd?
Currently, no hedge funds are holding shares in IN:SAKAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sakar Healthcare Ltd
Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable SVP in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in approximately 22 therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins. The company also exports its products to approximately 38 countries, including Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Jagsonpal Pharmaceuticals Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Syncom Formulation (India) Ltd.
―
Venus Remedies Limited
―